Joel L. Young, M.D.

441 South Livernois Road, Suite 100
Rochester Hills, Michigan 48307
Phone: 248-608-8800 / Fax: 248-608-2490 / E-mail: jyoung@rcbm.net

Research Studies

December 2021:	**Primary Investigator:** SP-624-201: A Multicenter, Double-blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of SP-624 in the Treatment of Adults with Major Depressive Disorder
May 2021:	**Primary Investigator:** 102044RCT: A Double-Blind, Randomized, Placebo-Controlled, Single-Center, Flexible Titration Study Evaluating the Efficacy of Solriamfetol in Treating Fatigue and Cognitive Symptoms in Adults Aged 18-65 Years with a Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
November 2020:	**Primary Investigator:** 33120100195: A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Adult Subjects With Borderline Personality Disorder
November 2020:	**Primary Investigator:** 33120100071: A Phase 3, Multicenter, Randomized, Double-blind Trial of Brexpiprazole as Combination Therapy with Sertraline in the Treatment of Adults with Post-traumatic Stress Disorder
November 2020:	**Primary Investigator:** 54135419TRD4005: A randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants with Treatment-resistant Depression.
January 2019:	**Primary Investigator:** 405-201-00014: A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults with Attention-deficit/Hyperactivity Disorder
January 2019:	**Primary Investigator:** 405-201-00015: An Open-label, 52-Week, Multicenter Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults with Attention-Deficit/Hyperactivity Disorder
November 2018:	**Primary Investigator**: 54135419MDD4001: Self-Reported Review of the Value of Esketamine (STRIVE) in Subjects with Treatment-Resistant Depression
October 2018:	**Primary Investigator**: 331-201-00079: A Phase 3, Multicenter, Randomized , Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole as Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder
August 2018:	**Primary Investigator**: AR19.004: A Multicenter, Fixed-Dose, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of AR19 (Amphetamine Sulfate) in Adult Subjects (Ages 18-55) with Attention Deficit Hyperactivity Disorder (ADHD)

May 2018:	**Primary Investigator**: LVM-MD-14: A Double-blind, Placebo-and Active-controlled Evaluation of the Safety and Efficacy of Levomilnacipran ER in Pediatric Patients 7-17 Years With Major Depressive Disorder
January 2018:	**Primary Investigator**: 42847922MDD2002 A 6-Month, Multicenter, Double-Blind, Randomized, Flexible-Dose, Parallel-Group Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Subjects With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
October 2017:	**Primary Investigator:** SEP360-321: A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults with Moderate to Severe Binge Eating Disorder
October 2017:	**Primary Investigator:** SEP360-322: An Open-label, Flexibly-dosed, Multicenter, Extension Study of Dasotraline to Evaluate Long-Term Safety and Tolerability in Adults with Binge-eating Disorder
September 2017:	**Primary Investigator:** SPD489-347: A Phase 3, Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled, Fixed-dose Safety and Efficacy Study of SPD489 Compared with Placebo in Preschool Children Aged 4-5 Years with Attention-deficit/Hyperactivity Disorder
September 2017:	**Primary Investigator:** SPD489-348: A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed with Attention-deficit/Hyperactivity Disorder
July 2017:	**Primary Investigator:** AEVI-001-ADHD-202: A Multicenter, 3-Part, 6-Week, Double-blind, Randomized, Placebo-controlled, Parallel-design Study to Assess the Efficacy and Safety of AEVI-001 in Children and Adolescents (Ages 6-17 Years) with Attention Deficit Hyperactivity Disorder and with or without Copy Number Variants in Specific Genes Implicated in Glutamatergic Signaling and Neuronal Activity.
May 2017:	**Primary Investigator:** EVA-19350: RE-kinect Study. Real-world Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents
March 2017:	**Primary Investigator:** 54135419TRD3008:An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression
December 2016:	**Primary Investigator**: MDGN-NFC1-ADHD-201: A Phase 2, Multicenter, 6-Week, Double-blind, Randomized, Placebo-controlled, Parallel-design Study to Assess the Efficacy and Safety of NFC-1 in Adolescents (Ages 12-17 Years) with Genetic Disorders Impacting Metabotropic Glutamate Receptors and Attention Deficit Hyperactivity Disorder
September 2016:	**Primary Investigator:** MDGN-NFC-ADHD-001: A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
June 2016:	**Primary Investigator**: ESKETINTRD3003: A Randomized, Double-blind, Multicenter, Active-controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression

March 2016:	**Primary Investigator:** NLS-1001: A Double-Blind, Placebo-Controlled, Phase 2 Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention Deficit Hyperactivity Disorder (ADHD)
September 2015:	**Primary Investigator:** SHP465-306: A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Forced-dose Titration, Safety and Efficacy Study of SHP465 in Adults Aged 18 -65 Years with Attention-Deficit Hyperactivity Disorder (ADHD)
July 2015:	**Primary Investigator:** ALCOBRA-AL016: A 10-week, Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine immediate-release/slow release, bilayer tablet) 1400mg Compared with Placebo in Adults with Attention Deficit/ Hyperactivity Disorder (ADHD)
June 2015:	**Primary Investigator:** SHP465-305: A Phase 3, Randomized, Double-blind, Multi-center, Placebo-controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years with Attention-Deficit Hyperactivity Disorder (ADHD)
May 2015:	**Primary Investigator:** SEP360-310: An Open-label, Flexibly-dosed, 26- Week Extension Safety Study of Dasotraline in Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
May 2015:	**Primary Investigator:** SEP360-202: A 6 week, Randomized, Multicenter, Placebo-controlled, Parallel-group Efficacy and Safety Study of Dasotraline versus Placebo in Subjects 6 to 12 Years of Age with Attention Deficit Hyperactivity Disorder (ADHD)
May 2015:	**Primary Investigator:** BNX-401: A Prospective Study of Treatment Satisfaction With Bunavail (Buprenorphine and Naloxone) Buccal Film in Opioid-Dependent Subjects
January 2015:	**Primary Investigator:** DS5565-A-E312: An Open-label Extension Study of DS-5565 For 52 Weeks In Pain Associated with Fibromyalgia
January 2015:	**Primary Investigator:** DS5565-A-E310: A Randomized, Double-blind, Placebo-and Active- Controlled Study of DS-5565 In Subjects with Pain Associated with Fibromyalgia
October 2014:	**Primary Investigator**: SEP360-301: A Randomized, Multicenter, Placebo-controlled, Parallel-group, Efficacy and Safety Study of 2 Doses of Dasotraline in Adults with Attention Deficit Hyperactivity Disorder (ADHD)
July 2014:	**Primary Investigator:** 331-13-214: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder
April 2014:	**Primary Investigator:** SPD489-346: A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy

	of SPD489 in Adults Aged 18-55 years with Moderate to Severe Binge Eating Disorder
March 2014:	**Primary Investigator:** ALCOBRA-AL012: A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared with Placebo in Adults with Attention Deficit/Hyperactivity Disorder (ADHD)
February 2014:	**Primary Investigator:** SEP-360-304: A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults with Attention Deficit Hyperactivity Disorder (ADHD)
December 2013:	**Primary Investigator:** 331-13-001: Phase 3b, Multicenter, Open-label Exploratory Trial to Evaluate the Efficacy, Safety, and Subject Satisfaction of Brexpiprazole as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy
August 2013:	**Primary Investigator: SPD489-345:** A Phase 3, Multicenter, Open-label, 12-month Extension Safety and Tolerability Study of SPD489 in the Treatment of Adults with Binge Eating Disorder.
July 2013:	**Primary Investigator:** SPD489-406: A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared with OROS-MPH (CONCERTA®) with a Placebo Reference Arm, in Adolescents Aged 13-17 Years with Attention-deficit/Hyperactivity Disorder (ADHD).
June 2013:	**Primary Investigator:** VLZ-MD-21**:** A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder
January 2013	**Primary Investigator:** SEP-225289: A Randomized, Double-blind, Parallel-group, Multicenter Efficacy and Safety Study of SEP-225289 versus Placebo in Adults with Attention Deficit Hyperactivity Disorder (ADHD).
January 2013	**Primary Investigator:** SPD489-344: A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years with Moderate to Severe Binge Eating Disorder"
July 2012	**Primary Investigator:** SPD489-405 A Phase 4, Randomized, Double-Blind, Multicenter, Parallel Group, Active-Controlled, Dose-Optimization Safety and Efficacy Study of SPD489 (VyvanseÒ) Compared with OROS-MPH (ConcertaÒ) with a Placebo Reference Arm, in Adolescents Aged 13-17 Years with Attention-Deficit/Hyperactivity Disorder (ADHD)
July 2012	**Primary Investigator (IST):** ADINT2012: A Double-Blind, Randomized, Placebo-Controlled, Single-Center, Dose Optimization Study Evaluating the Efficacy and Safety of guanfacine hydrochlordie in Combination with Psychostimulants in Adults Aged 18-65 Years with a Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)

May 2012	**Primary Investigator:** SPD503-210: A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 years with Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
April 2012	**Primary Investigator:** VLZ-MD-02: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study with Vilazodone in Patients with Major Depressive Disorder
September 2011:	**Primary Investigator:** MLN-MD-29: A Multicenter, Open-Label, 52-Week Extension Study to Evaluate the Safety and Efficacy of Milnacipran in Pediatric Patients with Primary Fibromyalgia
July 2011:	**Primary Investigator:** Lu AA21004-314: A Phase 3, Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 (15 and 20 mg) in Subjects with Major Depressive Disorder
July 2011:	**Primary Investigator:** 331-10-238: A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults with Major Depressive Disorder, the Orion Trial
June 2011:	**Primary Investigator:** SPD489-317: A Phase 3b, Double-blind, Randomised, Active-controlled, Parallel group Study to Compare the Time to Response of Lisdexamfetamine Dimesylate to Atomoxetine Hydrochloride in Children and Adolescents aged 6 17 years with Attention Deficit/Hyperactivity Disorder (ADHD) Who Have Had an Inadequate Response to Methylphenidate Therapy
May 2011	**Primary Investigator:** Lu AA21004_315:A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Duloxetine-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (15 and 20 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
May 2011:	**Primary Investigator:** 331-10-227: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder, the Polaris Trial
May 2011:	**Primary Investigator:** SPD503-312: A Phase 3, Double-blind, Randomized, Multi-center, Placebo-controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once-daily Dosing with Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 years Diagnosed with Attention-deficit/Hyperactivity Disorder (ADHD)
May 2011:	**Primary Investigator:** MLN-MD-14: A Multicenter, Randomized, Double-Blind, Placebo Controlled Withdrawal Study to Evaluate the Safety, Tolerability, and Efficacy of Milnacipran in Pediatric Patients with Primary Fibromyalgia
April 2011:	**Primary Investigator:** A3051073-1013: A Twelve-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study with Follow-Up Evaluating the Safety and Efficacy of Varenicline for Smoking Cessation in Healthy Adolescent Smokers
March 2011:	**Primary Investigator:** SPD503-316: A Phase 3, Randomized, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Reference, Dose-Optimization Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in

	Children and Adolescents aged 6-17 years with Attention-Deficit/Hyperactivity Disorder
February 2011:	**Primary Investigator:** 331-08-212: A Phase 2, Multicenter, Open-label Study to Assess the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adult Patients with Major Depressive Disorder
June 2010:	**Primary Investigator:** CAGO178C2399 A 52-week, multi-center, open-label study of the safety and tolerability of agomelatine sublingual tablets in patients with Major Depressive Disorder (MDD)
Oct 2010:	**Primary Investigator:** Protocol A3331017: A Randomized Phase 2A, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of CP-601,927 Augmentation of Antidepressant Therapy in Major Depression
Oct. 2010:	**Primary Investigator:** CILO522DUS01: A 12-week, Randomized, Multi-center, Open-Label, iloperidone, (12-24mg/day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone,Olanzapine or Aripiprazole (i-FANS) (IND 36,827 - Phase IV study)
May 2010:	**Primary Investigator:** SPD503-314 A Phase 3, Double-blind, Randomized, Multicenter, Placebo-controlled, Dose Optimization Study Evaluating the Tolerability and Efficacy of AM and PM Once Daily Dosing with Extended-release Guanfacine Hydrochloride in Children Aged 6-12 with a Diagnosis of Attention-Deficit/Hyperactivity Disorder
April 2010:	**Primary Investigator:** F1J-MC-HMCK A Double-Blind, Efficacy and Safety Study of Duloxetine versus Placebo in the treatment of Children and Adolescents with Major Depressive Disorder
February 2010:	**Primary Investigator:** SPD489-403 A Phase 4, Randomized, Double-blind, Multi-Center, Placebo-controlled, Parallel Group Study Evaluating the Safety and Efficacy of SPD489 on Executive Function (Self-regulation) Behaviors in Adults with Attention Deficit/Hyperactivity Disorder (ADHD) Reporting Clinically Significant Impairment of Real-world Executive Function Behavior
February 2010:	**Primary Investigator:** Otsuka 331-08-213 A Phase 2, Multicenter, Randomized, Double blind, Placebo-controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adult Attention-deficit/Hyperactivity Disorder
September 2009:	**Primary Investigator:** HP9-MC-LNDH Long-Term, Open-Label, Safety Study of LY2216684 in Pediatric Patients with Attention Deficit/Hyperactivity Disorder.
September 2009:	**Primary Investigator:** RCBM11: Use of Lisdexamfetamine Dimesylate in the Treatment of Cognitive Impairment (Chronic Fatigue Syndrome): A Double-Blind, Placebo-Controlled Study.
June 2009:	**Primary Investigator:** CONCERTA-ATT-3014: A Placebo-Controlled, Double-blind, Parallel-Group, Individualized Dosing Study Optimizing Treatment of Adults

with Attention Deficit Hyperactivity Disorder to an Effective Response with Oros Methylphenidate.

June 2009: **Primary Investigator:** HP9-MC-LNBF: A Fixed-Dose, Randomized, Double-Blind, Placebo-Controlled Study of LY2216684 in Children and Adolescents with Attention Deficit/Hyperactivity Disorder

May 2009: **Primary Investigator:** 31001074 ATT 2001: A Randomized, Double-Blind, Placebo-and Active-Controlled, Parallel-Group, Multicenter Study 3 Dosages of JNJ-31001074 in the Treatment of Adult Subjects w/Attention-Deficit/Hyperactivity Disorder.

March 2009: **Primary Investigator:** SPD489-401 A Phase 4, Double-blind, Multi-center, Placebo-controlled, Randomized Withdrawal, Safety and Efficacy Study of SPD489 in Adults Aged 18-55 with Attention-Deficit/Hyperactivity Disorder (ADHD)

August 2008: **Sub-Investigator:** SPD503-313-A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center, Dose Optimization Study Evaluating the Efficacy and Safety of SPD503 in Combination with Psychostimulants in Children & Adolescents Aged 6-17 Years with a Diagnosis of Attention-Deficit/Hyperactivity Disorder

January 2008: **Primary Investigator:** CAGO178A2305-An 8-Week, Multi-Center, Randomized, Double-Blind, Placebo and Paroxetine-Controlled Study of the Efficacy, Safety, and Tolerability of Agomelatine 25mg and 50mg given once daily in the treatment of Major Depressive Disorder (MDD) followed by a 28-week Open-Label, Treatment with Agomelatine 25mg or 50 mg.

2007: **Sub-Investigator:** SPD485-409 – A Phase IIIB Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Dose Optimization Study, Designed to Evaluate the Efficacy and Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years with Attention Deficit/Hyperactivity Disorder (ADHD).

2007: **Sub-Investigator:** SPD485-410 – A Phase IIIB Long-Term, Open-Label, Multi-Center, Extension Study Designed to Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years with Attention Deficit/Hyperactivity Disorder (ADHD).

2007: **Primary Investigator:** CAGO178A2301-An 8-Week, Randomized, Double-Blind, Fixed-Dosage, Placebo-Controlled, Parallel-Group, Multi-Center study of the Efficacy, Safety and Tolerability of Agomelatine 25mg and 50 mg in the Treatment of Major Depressive Disorder (MDD) Followed by a 52-week, Open-Label Extension.

2007: **Primary Investigator:** CENA713D_US38 A Prospective, 5-Week, Open-Label, Randomized, Multi-Center, Parallel-Group Study with a 20-week, Open-Label Extension Evaluating the Tolerability and Safety of Switching from Donepezil to an initial dose of 5cm2 Rivastigmine Patch Formulation in Patients with Probable Alzheimer's Disease.

2006: **Primary Investigator**: CENA713BUS32 – A Prospective, 26-Week, Open-Label, Multi-Center, Single-Arm Pilot Study to Evaluate the Safety and Tolerability of

Exelon Capsule with Add on Memantine HCI in Patients with Probable Alzheimer's Disease.

2006: **Primary Investigator**: Amethyst Study D1448C00005 – A Multi-Center, Double-Blind, Randomized-Withdrawal, Parallel-Group, Placebo-Controlled Phase II Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Released (Seroquel SR) as Monotherapy in the Maintenance Treatment of Patients with Major Depressive Disorder Following an Open-Label Stabilization Period.

2005: **Sub-Investigator**: 31-03-240 – A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Two Fixed Oral Doses of Aripiprazole (10mg or 30mg) in the Treatment of Child and Adolescent Patients, Ages 10-17 Years, with Bipolar I Disorder, Manic or Mixed Episode with or without Psychotic Features.

2005: **Sub-Investigator**: 31-03-241 – A Multi-Center, Open-Label, Safety and Tolerability Study of Flexible-Dose Oral Aripiprazole (2mg-30mg) in the Treatment of Adolescent Patients with Schizophrenia, and Child and Adolescent Patients with Bipolar I Disorder, Manic or Mixed Episode.

2005: **Sub-Investigator**: SPD465-303 – A Phase III, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group, Forced-Dose Titration Safety and Efficacy Study of SPD465 in Adults with Attention-Deficit/Hyperactivity Disorder (AD/HD).

2005: **Sub-Investigator**: SPD465-304 – A Phase III, Multi-Center, 12-Month, Open-Label Safety Study of SPD465 in Adults with Attention-Deficit/Hyperactivity Disorder (AD/HD).

2005: **Sub-Investigator**: B4Z-US-LYDQ – A Double-Blind, Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults with AD/HD and Comorbid Social Anxiety Disorder.

2005: **Primary Investigator**: SP851 – A Multi-Center, Randomized, Open-Label, Parallel Design Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment with Niravam and an SSRI or SNRI to Treatment with an SSRI or SNRI Alone in Subjects with Generalized Anxiety Disorder or Panic Disorder.

2004: **Sub-Investigator**: LYCD – Maintenance of Benefit after 8-Week and 52-Week Treatment with Atomoxetine Hydrochloride in Adolescents with Attention-Deficit/Hyperactivity Disorder.

2004: **Primary Investigator**: LEAPS – Lilly's Emotional and Physical Symptoms of Depression Study: To Assess the Effectiveness of Duloxetine 60mg Once Daily (QD) in Diverse Populations of Outpatients with MDD in Practice-Based Clinical Settings.

2004: **Primary Investigator**: LYCW – A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults with Attention-Deficit/Hyperactivity Disorder: With a Secondary Examination of Impact of Treatment on Family Functioning.

2003: **Primary Investigator**: SCA 40917 – Optimizing Administration of Lamictal: An Open-Label Study of Tolerability, Clinical Response and Satisfaction in Adult Bipolar I Subjects, Optimizing Initiation of Therapy Using Administration of Dermatological Precautions and Lamictal Titration Packs.

2003: **Primary Investigator**: SLI 381-312 – A Phase IIIB, Open-Label, Multi-Center Study to Assess Safety, Tolerability and Effectiveness Associated with the Use of Adderall XR in Adults with AD/HD and Evaluate an AD/HD-Specific Novel Quality of Life Measure.

2003: **Co-Investigator**: ISS-2003-021 CAFTRED – The Effect of Concerta on Adults with Treatment Resistant Depression (TRD) and AD/HD: A Double-Blind, Placebo-Controlled Study.

2002: **Primary Investigator**: CD00500 – Metadate CD Extended-Release Capsules in the Management of AD/HD: A Multi-Center, Open Label, Post-Marketing Clinical Experience Study.

2002: **Primary Investigator**: An Open-Label Community Assessment Trial of Adderall XR in Pediatric AD/HD.

2002: **Primary Investigator**: Protocol B4Z-MC-LYAX – A Randomized, Double-Blind, Placebo-Controlled Study of Atomoxetine Hydrochloride in Adolescents with Attention-Deficit/Hyperactivity Disorder and Comorbid Depressive Disorder.

2002: **Primary Investigator**: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Safety and Efficacy Study of SPD 420 in Adults with Attention-Deficit/Hyperactivity Disorder (AD/HD).

2001 – 2002: **Primary Investigator**: An Open-Label, Multi-Center Study to Assess Tolerability, Effectiveness and Quality of Life Associated with the Use of SLI 381 (Adderall XR) in Children with Attention-Deficit/Hyperactivity Disorder in a Community Practice Setting.

2001: **Primary Investigator**: Metadate CD Extended-Release Capsules (CII) in the Management of Attention-Deficit/Hyperactivity Disorder: A Multi-Center, Open-Label, Post-Marketing Clinical Experience Study.

1998 – 2000: Study of Safety of Long-Acting Methylphenidate on Diverse Attention-Deficit/Hyperactivity Disorder Population.

1993: Anti-Convulsant Properties of ECT and Clinical Response. Young, J; Tandon, R; Greden, J; Abstract, American Psychiatric Association, May, 1993.

1989 – 1991: **Co-Investigator**: Study of the Efficacy of Intraduodenal Infusion of Liquefied L-DOPA in Advanced Parkinson's Disease. LeWitt, P.

Publications/ Publication Contributions

November, 2023	Development and validation of the ADHD Symptom and Side Effect Tracking – Baseline Scale (ASSET-BS): a novel short screening measure for ADHD in clinical populations, With Richard N. Powell, Celeste Zabel, Jaime Saal, Lisa L. M. Welling, Jillian Fortain, Ashley Ceresnie *BMC Psychiatry*
February, 2023	Adults Living Well with ADHD: At Home, At Work, and With Friends Vol. 9, brochure
May, 2022	Clinical Response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder, With Greg W. Mattingly, Richard H Weisler, Ben Adeyi, Bryan Dirks, Thomas Babcock, Robert Lasser, Brian Scheckner, and David W Goodman
May, 2022	Adults Living Well with ADHD: At Home, At Work, and With Friends, brochure
August, 2021	A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of AR19, a Manipulation-Resistant Formulation of Amphetamine Sulfate, in Adults With Attention-Deficit/Hyperactivity Disorder With Stephen V. Faraone, PhD; Ann Childress, MD; Steve Caras, MD, PhD; Valerie K. Arnold, MD; C. Brendan Montano, MD; Elias H. Sarkis, MD; Andrew J. Culter, MD *The Journal of Clinical Psychiatry*
January, 2021	A Clinician's guide for navigating the world of attention deficit hyperactivity disorder medications, With Gregory W Mattingly
December, 2020	Conquering Your Fibromyalgia, Introduction, With M. Lenz, MD.
August, 2020	Understanding and Treating Chronic Fatigue: A Practical Guide for Patients, Families, and Practitioners, ABC Clio's Praeger Press.
July, 2016	Atomoxetine Increased Effect over Time in Adults with Attention-Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double-Blind, Placebo-Controlled, Randomized Trials. With Wietecha et al. *CNS Neuroscience and Therapeutics.*
February, 2016	Supplementary guanfacine hydrochloride as a treatment of attention deficit hyperactivity disorder in adults: A double blind, placebo-controlled study. With M Butterfield and J Saal. *Psychiatry Research.*
November, 2016	Adult Attention-Deficit/Hyperactivity Disorder Diagnosis, Management, and Treatment in the DSM-5 Era. With D Goodman, MD. *Primary Care Companion.*
November, 2015	A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder," J. Am. Acad. Child Adolesc. Psychiatry
October, 2014	"Efficacy of Guanfacine Extended Release Assessed During the Morning, Afternoon, and Evening Using a Modified Conners' Parent Rating Scale-Revised: Short Form," Journal of Child and Adolescent Psychopharmacology, Vol. 24, No. 8, 2014.

July, 2014	Recognizing and treating attention-deficit/hyperactivity disorder in college Students. With Frances Prevatt. *Journal of College Student Psychotherapy.*
December, 2013	When Your Adult Child Breaks Your Heart: Coping with Mental Illness, Substance Abuse, and the Problems that Tear Families Apart, Globe Pequot Lyons Press.
January, 2013	Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. With Mattingly GW, Weisler RH, Young J, Adeyi B, Dirks B, Babcock T, Lasser R, Scheckner B, Goodman DW. *BMC Psychiatry*
January, 2013	Chronic fatigue syndrome: 3 cases and a discussion of the natural history of attention-deficit/hyperactivity disorder. *Postgraduate Medicine.*
October, 2012	"Use of lisdexamfetamine dimesylate in treatment of executive functioning deficits and chronic fatigue syndrome: A double blind, placebo-controlled study." *Psychiatry Research.*
September, 2012	Discontinuity in the Transition from Pediatric to Adult Health Care for Patients with Attention-Deficit/Hyperactivity Disorder. With B Montano. *Postgraduate Medicine.*
September, 2012	"Delusional Parasitosis in a Female Treated with Mixed Amphetamine Salts: A Case Report and Literature Review" With M Buscarino and J Saal. *Case Reports in Psychiatry.*
June, 2012	"Atomoxetine Once Daily for 24 Weeks in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD): Impact of Treatment on Family Functioning" Clinical Neuropharmacology
September, 2011	"Siblings of adolescents with ADHD who themselves have ADHD are more likely to have psychiatric comorbidities than are unaffected siblings or controls without ADHD." Evidence-Based Mental Health.
March, 2011	"Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial." Clinical Neuropharmacology.
2011	"Clinical Consultations: Reassessing Patients with ADHD," Volume 1, Edition 1, Clinical Handout.
December, 2010	"Individualizing Treatment for ADHD: An Evidence-Based Guideline," Medcape Education Psychiatry and Mental Health. Available at: http://www.medscape.org/viewarticle/734449
November, 2010	"ADHD in Adults with Medical or Psychiatric Comorbidities" Medscape CME Psychiatry and Mental Health. Available at: http://cme.medscape.com/viewarticle/731850.
August, 2010	"Advances in Adult AD/HD Research" Medscape CME Psychiatry and Mental Health. With A Rostain, R White, C Surman, and J Covino. Available at: http://cme.medscape.com/viewprogram/31435.

April, 2010	"ADHD and Crime: Considering the Connections" Medscape CME Psychiatry and Mental Health. Available at: http://cme.medscape.com/viewarticle/719862
January, 2010	"Panel Discussion: New Therapeutic Options for Childhood Attention-Deficit/Hyperactivity Disorder," The Journal of Medicine.
January, 2010	"Panel Discussion: Strategies for Managing Disruptive Behavioral Disorders in Children and Adolescents," The Journal of Medicine.
January, 2010	"Panel Discussion: Educating Patients with Attention Deficit/Hyperactivity Disorder," The Journal of Medicine.
January, 2010	"Panel Discussion: Appropriate Diagnosis of Attention Deficit/Hyperactivity Disorder," The Journal of Medicine.
January, 2010	"Panel Discussion: The Natural History and Diagnostic Evaluation of Attention Deficit/Hyperactivity Disorder," The Journal of Medicine.
January, 2010	"Panel Discussion: Treatment Options for Complex Pediatric Attention Deficit Hyperactivity Disorder Cases," The Journal of Medicine.
December, 2009	"Why Now? Factors that Delay ADHD Diagnosis in Adults" Medscape CME Psychiatry and Mental Health. Available at: http://cme.medscape.com/viewarticle/713528
November, 2009	"Women with ADHD: Unique Presentations and Treatment Approaches," Medscape CME Psychiatry and Mental Health. Available at: http://cme.medscape.com/viewarticle/711520

October, 2009	"Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder," with Weisler, R; Mattingly, G; Gao, J; Squires, L; Adler, L. In CNS Spectrums.
September, 2009	Contemporary Guide to Adult ADHD, Handbooks in Healthcare
September, 2009	"ADHD in Adults with Medical Comorbidities," Medscape CME Psychiatry and Mental Health. Available at: http://cme.medscape.com/viewarticle/708287.
June, 2009	"ADHD and Psychiatric Comorbidities: Treatment Approaches to Improve Outcomes," Medscape CME Psychiatry and Mental Health. Available at: http://cme.medscape.com/viewarticle/704639.
May, 2009	Contribution to "Combat Duty Harms Long-Term Health of Vets," Serena Gordon, Health Day: http://www.healthday.com/Article.asp?AID=626429
November, 2008	"Advances in AD/HD Management: Maximizing Effects While Minimizing Side Effects of Treatment," Medscape CME. Available at: http://cme.medscape.com/viewprogram/17687.
October, 2008	"Clinical Update on Adult AD/HD," in *Family Therapy Magazine.*
September, 2008	"Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention deficit/hyperactivity disorder." With Adler, L.A.; Goodman, D.W.; Kollins, S.H.; Weisler, R.H.; Krishnan, S; Zhang, Y; Biederman, J, in the Journal of Clinical Psychiatry.
September, 2008	"*New Medical School Brings Mental Health Outreach Opportunities"* in Mental Illness Research Association (MIRA) Newsletter
August, 2008	"Common Comorbidities Seen in Adolescents with Attention Deficit/Hyperactivity Disorder," in ADHD/Learning Disorders. *Editors: Arthur Robin, PhD; Howard Schubiner, MD; William L. Coleman, M.D.*
2007	A Postmarketing Clinical Experience Study of Metadate CD, Medscape URL: http://doctor.medscape.com/viewarticle/446549 With co-investigators
July, 2008	ABSTRACT: "Long-Term Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults with Attention-Deficit/Hyperactivity Disorder," with Richard Weisler, MD; Greg Mattingly, MD; Joseph Gao; Liza Squires, MD; and Lenard Adler, MD16, 2008
June 17, 2008	Contribution to "Weighing Nondrug Options for AD/HD," in *The New York Times,* Article by Tina Parker-Pope
June 16, 2008	Contribution to "Making Mistakes: Admitting them and Learning from them," in *The Macomb Daily*, article by Stephen Bitsoli.
February, 2008	Contribution to "Advances in ADHD Management: Improving Outcomes in Adult ADHD," Medscape CME. Available at: http://cme.medscape.com/viewprogram/8787.

February, 2008	"Optimizing Patient Outcomes in Adult AD/HD: Current and Emerging Therapies, in *Advances in Psychiatric Medicine,* supplement to *Psychiatric Times*
January, 2008	"Adolescent Suicide" in the *Michigan Psychiatric Society Newsletter*, with Birgit Amann, M.D.
November, 2007	"Fibromyalgia, Chronic Fatigue, and Adult Attention Deficit Hyperactivity Disorder in the Adult: A Case Study,"*Psychopharmacology Bulltein, Volume 40: Number 1,* with Judy Redmond, M.A.
June, 2007	"ADHD and Fibromyalgia: Related Conditions?," in Fibromyalgia: The Complete Guide From Medical Experts and Patients, published by Jones and Bartlett, Inc.
May, 2007	"Rochester doctor aims to demystify what's really behind adult AD/HD," The Oakland Press- "Good Health" section (Joel L.. Young, M.D. (interviewed by Jane Peterson, columnist for the Oakland Press)
May, 2007	"ADHD Summer Survival Tips", in *WebMD the Magazine*, with Denise Mann
May, 2007	"Straight Talk About AD/HD: A 5-Part Video Series," Eli Lilly and Company.
January, 2007:	ADHD Grown Up: A Guide to Adolescent and Adult ADHD, published by W.W. Norton & Company, Inc.
October, 2006	"Treatment of AD/HD and Comorbid Disorders," in CNS Spectr.
August, 2006	Contribution to "Ten Common Behavioral Problems in Children" in Metro Parent Magazine, with Alice Rhein.
June, 2006	Contribution to "The Use of Psychiatric Medications in Children and Teens" in Metro Parent Magazine, with Kim Kovelle.
March, 2006:	"Focusing on AD/HD" – Web Site: HealthNewsDigest.com. (Joel L. Young, M.D. interviewed by Lee Degenstein, columnist for HealthNewsDigest.com).
May, 2005:	"A Closer Look at Substance Use Disorders in Individuals with AD/HD," A CME Monograph Sponsored by the University of Michigan Medical School. Wilens, Riba, Young, et. al. Prepared by the JB Ashtin Group, Inc.
April, 2005:	"AD/HD Affects All", The Oakland Press – "My Body My Health" – A Monthly Special Section.
February, 2005:	"An unnecessary scare", Michigan Psychiatric Society Newsletter, pp. 11-12.
December, 2004:	"AD/HD & Depression: Learning from Case Studies", Attention Magazine, pp. 20-25.
November 7, 2004:	"State should put Strattera back on preferred drug list", (Co-author: Birgit Amann, M.D.), The Oakland Press.

2004:	Videotape by Eli Lilly and Co.: "Solutions for Wellness: A Behavioral Approach to Weight Management During Antipsychotic Treatment", (Featured Physicians: Joel L. Young, M.D., and Birgit Amann, M.D.).
Fall, 2004:	DVD by Eli Lilly and Co.: "An Introduction to the Solutions for Wellness: Personalized Program", (Featured Physician: Joel L. Young, M.D.).
Fall, 2004:	"AD/HD: A Brief Overview", MIRA Reporter (Mental Health Research Association), v.11, #3.
Fall, 2004:	"The Politics of AD/HD: An Interview with Joel Young, M.D. – Second in a Series", FOCUS Newsletter (Attention Deficit Disorder Association).
Summer, 2004:	"Diagnosis for the Entrepreneur: An Interview with Joel Young, M.D. - First in a Series", FOCUS Newsletter (The Attention Deficit Disorder Association).
July 23, 2004:	Co-Faculty Editor: "A Closer Look at Substance Use Disorder in Individuals with AD/HD", a CME Monograph sponsored by The University of Michigan Medical School and supported by Shire US Inc.
December, 2003:	"Just What is Coaching" (with David Giwerc), Attention Magazine, pp. 36-45.
October, 2003:	"Attention-Deficit/Hyperactivity Disorder in Adolescent Males" (Schubiner H., Robin A. L., Young, J.), Adolescent Medicine, 14(3):663-76, vii-viii.
May 23, 2003:	"Foster Parents Underfunded", Detroit Free Press.
February, 2003:	"Nonstimulant Treatment Options for AD/HD", Teaching Chapter, AD/HD: New AD/HD Treatment Options for Optimizing Outcomes, Editor-in-Chief: Joseph Biederman, M.D., #4, pp. 29-36.
2002:	"Depression and Anxiety in Women with AD/HD", Textbook Chapter, Gender Issues and AD/HD, Editors: P. Quinn and K. Nadeau, pp. 270-288.
May/June, 2002:	"AD/HD in Adults: Contemporary Approaches", Behavioral Health Management, Editorial Director: Richard L. Peck, v.22, #3, pp. 21-28.
Jan./Feb., 2001:	"AD/HD: The Parents' Struggle", ADDvance Magazine, v.4, #3, pp. 28-29.
August 5, 2000:	"One-a-Day Dose Now an Option for ADD", Interviewed/Quoted, The Detroit News & Free Press.
April 23, 2000:	"Physician Defends Use of Ritalin", The Daily Tribune.
April 6, 2000:	"Treatment Key for Kids' Mental Health" (co-author: Birgit Amann, M.D.), Detroit Free Press.
2000:	"Don't Neglect Students' Mental Health," Detroit Free Press.
2000:	Videotape: "Me, My AD/HD Coach and Me" (produced by David Giwerc).
1999:	"Less Sociology, More Psychiatry in Youth Violence Debate", Detroit Free Press.

August 29, 1999: "Don't Neglect Students' Mental Health", Detroit Free Press.

April 4, 1999: "Special Doctor, Special Lessons", Detroit Free Press.

November 2, 1998: "Human Brain Yields its Secrets", Detroit Free Press.

November 2, 1993: "Attention Disorder Can Afflict Adults" (with Steven Spector, Ph.D.), Detroit Free Press.

Poster Presentations

October, 2023 Mattingly, G., Young, J., Earnest, J., Koch, J., Qin, P., Rubin, J., Efficacy of Viloxazine ER (Qelbree) for ADHD in Adults Based on Prior Stimulant Exposure

January, 2022 Young, J., Powell, R., Young, B., Welling, L., & Zabel, C., (2022, January 14-16). Adult ADHD and Restless Leg Syndrome (RLS): Examining the Correlation between ADHD Symptom Severity and Presence of RLS [Conference poster presentation]. *American Professional Society of ADHD and Related Disorders*. 2022 Virtual Conference.

January, 2017 Young, JL, Butterfield M, Ceresnie A, Saal J, Young, B (2017, January 14-16). Collateral Reporter to use Relationship Strength and Patient Age to Gauge Mental Health Risk [Conference poster presentation]. American Professional Society of ADHD and Related Disorders. 2017 Conference.

May, 2012 Use of lisdexamfetamine dimesylate in treatment of cognitive impairment and fatigue (Chronic Fatigue Syndrome): A double-blind, placebo-controlled study. Poster presentation at 2012 American Psychiatric Association Conference, May 7, 2012. Poster #34399 .

May, 2012 "ADHD is a notable characteristic of patients suffering from chronic lyme disease: a survey of adults at the Michigan Lyme Disease Association Conference." Poster presentation at 2012 American Psychiatric Association Conference, May 8, 2012. Poster # 34406.

November, 2011 Use of lisdexamfetamine dimesylate in treatment of cognitive impairment and fatigue (Chronic Fatigue Syndrome): A double-blind, placebo-controlled study. Poster presentation at 2011 U.S. Psych and Mental Health Congress, November 8, 2011. Poster # 110.

November, 2011 "ADHD is a notable characteristic of patients suffering from chronic lyme disease: a survey of adults at the Michigan Lyme Disease Association Conference." Poster presentation at 2011 U.S. Psych and Mental Health Congress, November 8, 2011. Poster # 111.